🔴 Adaptive Biotechnologies is trading 5.1% down in pre-market with no clear company-specific catalyst

Adaptive Biotechnologies is trading at $24.32, down 5.07%, with no identified company-specific announcement explaining the October 15 pre-market decline.

• The reported COO share sale was executed under a pre-arranged Rule 10b5-1 plan and does not establish a direct catalyst.
• The decline coincides with hotter-than-expected U.S. inflation and a 1.26% drop in the Nasdaq Composite, which may be weighing on growth-sensitive shares.
• Q3 results are scheduled for November 4; the report is not a same-day earnings catalyst.